Purpose

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Written informed consent obtained prior to the initiation of study procedures. - Men ≥ 18 years of age. - Histologically documented prostatic adenocarcinoma. - History of Castration-Resistant Prostate Cancer.

Exclusion Criteria

  • Known M1 disease. - Undergone imaging study for metastatic prostate cancer ≤ 3 months. - ECOG performance status ≥ 3. - Known malignant pleural effusions or ascites. - Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).

Study Design

Phase
Study Type
Observational
Observational Model
Case-Only
Time Perspective
Prospective

More Details

Status
Terminated
Sponsor
Dendreon

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.